These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 32404048)
1. Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database. Yu S; Zhang Y; Yao Y; Cao H J Headache Pain; 2020 May; 21(1):53. PubMed ID: 32404048 [TBL] [Abstract][Full Text] [Related]
2. Health care resource utilization following initiation of a triptan: a retrospective claims analysis. Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641 [TBL] [Abstract][Full Text] [Related]
3. Administrative prevalence and incidence, characteristics and prescription patterns of patients with migraine in Germany: a retrospective claims data analysis. Roessler T; Zschocke J; Roehrig A; Friedrichs M; Friedel H; Katsarava Z J Headache Pain; 2020 Jul; 21(1):85. PubMed ID: 32631274 [TBL] [Abstract][Full Text] [Related]
4. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States. Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063 [TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and predictors of costs among patients with migraine: evidence from the United States medical expenditure panel survey. Ford JH; Ye W; Nichols RM; Foster SA; Nelson DR J Med Econ; 2019 Sep; 22(9):849-858. PubMed ID: 30977712 [No Abstract] [Full Text] [Related]
6. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response. Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301 [TBL] [Abstract][Full Text] [Related]
7. Cost of pain medication to treat adult patients with nonmalignant chronic pain in the United States. Rasu RS; Vouthy K; Crowl AN; Stegeman AE; Fikru B; Bawa WA; Knell ME J Manag Care Spec Pharm; 2014 Sep; 20(9):921-8. PubMed ID: 25166291 [TBL] [Abstract][Full Text] [Related]
8. Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study. Lipton RB; Munjal S; Buse DC; Bennett A; Fanning KM; Burstein R; Reed ML Headache; 2017 Jul; 57(7):1026-1040. PubMed ID: 28603893 [TBL] [Abstract][Full Text] [Related]
9. Migraine Prophylaxis and Acute Treatment Patterns Among Commercially Insured Patients in the United States. Woolley JM; Bonafede MM; Maiese BA; Lenz RA Headache; 2017 Oct; 57(9):1399-1408. PubMed ID: 28842990 [TBL] [Abstract][Full Text] [Related]
10. Real-world assessment of concomitant opioid utilization and associated trends in patients with migraine. Kangethe A; Polson M; Evangelatos TM; Speicher LC; Tenaglia AT; Staats PS; Liebler EJ; Mwamburi M Am J Manag Care; 2020 Feb; 26(1 Suppl):S8-S14. PubMed ID: 32109019 [TBL] [Abstract][Full Text] [Related]
11. Factors Associated with Direct Health Care Costs Among Patients with Migraine. Bonafede M; Cai Q; Cappell K; Kim G; Sapra SJ; Shah N; Widnell K; Winner P; Desai P J Manag Care Spec Pharm; 2017 Nov; 23(11):1169-1176. PubMed ID: 29083975 [TBL] [Abstract][Full Text] [Related]
12. Migraine burden and costs in France: a nationwide claims database analysis of triptan users. Donnet A; Emery C; Aly S; Allaf B; Cayre F; Mahieu N; Gourmelen J; Levy P; Fagnani F J Med Econ; 2019 Jul; 22(7):616-624. PubMed ID: 30836035 [No Abstract] [Full Text] [Related]
13. Pharmaceutically treated comorbidities and associated healthcare costs among triptan users in Switzerland: A pharmacoepidemiological study from a nationwide health insurance database. Huber CA; Agosti R; Näpflin M; Blozik E Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):279-287. PubMed ID: 31828875 [TBL] [Abstract][Full Text] [Related]
14. Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks. Lee JH; Shewale AR; Barthold D; Devine B Headache; 2021 Nov; 61(10):1499-1510. PubMed ID: 34841520 [TBL] [Abstract][Full Text] [Related]
15. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes. Foster SA; Hoyt M; Ye W; Mason O; Ford JH Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723 [TBL] [Abstract][Full Text] [Related]
16. Acute migraine treatment with oral triptans and NSAIDs in a managed care population. Ng-Mak DS; Hu XH; Chen YT; Ma L Headache; 2008 Sep; 48(8):1176-85. PubMed ID: 18819177 [TBL] [Abstract][Full Text] [Related]
17. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA. Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555 [TBL] [Abstract][Full Text] [Related]
18. Prescription patterns in preventive and abortive migraine medication. Sumelahti ML; Mattila K; Sillanmäki L; Sumanen M Cephalalgia; 2011 Dec; 31(16):1659-63. PubMed ID: 22116941 [TBL] [Abstract][Full Text] [Related]
19. Characterization of Acute Prescription Migraine Medication Use: Results From the CaMEO Study. Hutchinson S; Lipton RB; Ailani J; Reed ML; Fanning KM; Adams AM; Buse DC Mayo Clin Proc; 2020 Apr; 95(4):709-718. PubMed ID: 32247344 [TBL] [Abstract][Full Text] [Related]
20. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. Schwedt TJ; Alam A; Reed ML; Fanning KM; Munjal S; Buse DC; Dodick DW; Lipton RB J Headache Pain; 2018 May; 19(1):38. PubMed ID: 29797100 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]